The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ
Explore this paper's citation graph
Summary
The decrease ratio of FDG accumulation of RCC lesions evaluated by PET/CT at 1 month after TKI treatment initiation was not influenced by the organs where the RCC metastasis was located, suggesting that TKIs can be used to treat patients with advanced RCC regardless of the metastatic site.
- Type
- article
- Published
- 2014-06-02
- Cited by
- 23
- References
- 27
- Access
- Open access
- OpenAlex
- https://openalex.org/W24885730
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:13383223
Keywords
Synthetic aperture radar, Azimuth, Remote sensing, Radar imaging, Computer science
References
- Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.
- Sorafenib in advanced clear-cell renal-cell carcinoma.
- Evaluation of Response to Multikinase Inhibitor in Metastatic Renal Cell Carcinoma by FDG PET/Contrast-Enhanced CT
- Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report
- Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
- Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
- Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
- Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography
- Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer
- 18F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study
- Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
- Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.
- Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis.
- Rising incidence of renal cell cancer in the United States.
- Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
- Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Cited by
- Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib
- PET/CT in renal, bladder and testicular cancer
- Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.
- Diagnostic Challenges of Kidney Cancer: A Systematic Review of the Role of Positron Emission Tomography-Computerized Tomography.
- Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT.
- The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations
- One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival
- Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation
- PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art
- PET/CT for the diagnostic assessment of patients with renal cancer
- Positron Emission Tomography in Renal Cell Carcinoma
- Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab
- Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma
- Therapeutic Efficacy of Tyrosine Kinase Inhibitors Treatment for Metastatic Renal Cell Carcinoma Using 18F-FDG PET/CT
- [68Ga]Ga-PSMA-HBED-CC PET/CT demonstrates to be superior to ceCT in detecting early treatment response in metastatic clear cell renal cell carcinoma
- Role of positron emission tomography/computed tomography in the evaluation of renal cell carcinoma
- Role of 18F-FDG PET/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy
- Applications of FDG PET in Oncology: Best Clinical Practice
- The 10th American Urological Association and the Japanese Urological Association International Affiliate Society Meeting
- The diagnostic performance of ^18F-FDG PET/CT in recurrent renal cell carcinoma: a systematic review and meta-analysis
Related papers
- Advanced Concepts for High-Resolution Wide-Swath SAR Imaging
- Digital beamforming and MIMO SAR: Review and new concepts
- Multidimensional waveform encoding for synthetic aperture radar remote sensing
- A golden age for spaceborne SAR systems
- Slow Pulse Repetition Interval Variation for High-Resolution Wide-Swath SAR Imaging
- An Overview of Three-Dimensional Imaging Technology and Technical Characteristics of SAR
- Forthcoming Spaceborne SAR Development
- The New Concept and Key Technology of Synthetic Aperture Radar System